| Autor: |
Marcin Kunecki, Tomasz Oleksy, Jan Martynów, Michalina Zygmunt, Marek Deja, Tomasz Kargul, Jolanta Biernat, Piotr Podolec, Krzysztof S. Gołba, Wojciech Płazak |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
BMC Pharmacology and Toxicology. 24 |
| ISSN: |
2050-6511 |
| DOI: |
10.1186/s40360-023-00660-3 |
| Popis: |
Background Previous studies on animal models have suggested that δ-opioid receptor (OR) signaling is the primary pathway responsible for opioids' cardioprotective effect. We hypothesize that the μ-OR's activation protects the human heart muscle. Methods We performed the experiments on muscular trabeculae obtained from the right atrial appendages of 104 consecutive patients subjected to coronary artery bypass surgery. Two trabeculae from each patient were studied simultaneously and exposed to 60 min of hypoxia with subsequent 60 min of reoxygenation. Remifentanil (5 μM or 50 μM) or sufentanil (40 μM or 400 μM) was used from the time of reoxygenation. Trabeculae contractility was assessed as the maximal amplitude of the contraction at baseline, after 60 min of hypoxia, during reoxygenation, and after norepinephrine application. Results During reperfusion, the application of remifentanil improved cardiomyocytes' function as compared to the control group (time from reperfusion: 15 min: 39.8% vs. 21.7%, p = 0.01; 30 min: 41.4% vs. 21.8%, p = 0.01; 60 min: 42.7% vs. 26.9%, p = 0.04; after norepinephrine: 64.7% vs. 43.2%, p = 0.03). The application of sufentanil did not influence cardiomyocyte function as can be seen when comparing the results of the experimental and control group. Conclusions Remifentanil, but not sufentanil, induces a cardioprotective effect on human right atria muscle in in vitro conditions, manifested as the increased amplitude of their contraction during reperfusion after 60 min of ischemia. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink